Financial News

EOC to Start China Trial of Novel Immunotherapy for Breast Cancer

EOC Pharma, a Shanghai oncology company, announced approval to start a China Phase II trial of a novel immunotherapy for patients with metastatic breast cancer. EOC in-licensed China rights to EOC202 (eftilagimod alpha) from Immutep of Australia . Efti, a soluble LAG-3 fusion protein (LAG-3Ig), is a novel antigen presenting cell (APC) activator being tested in cancer and infectious disease. It will be administered in combination with paclitaxel. EOC was spun out of China in-licensing company Eddingpharm in 2015. More details.... Stock Symbols: (ASX: IMM; NSDQ: IMMP) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info